Prospective observational study of sirolimus as primary immunosuppression after renal transplantation

Transplantation

Volumn 88, Issue 8, 2009, Pages 1010-1018

  Pescovitz, Mark D ^a,l   Nezakatgoo, Nosratollah ^b   Lorber, Marc I ^c   Nashan, Bjorn ^d   Tedesco Silva, Helio ^e   Kasiske, Bertram L ^f   De La Cruz, Federico J Juarez ^g   Russ, Graeme ^h   Campistol, Joseph ⁱ   Keown, Paul A ^j,k  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^f HENNEPIN COUNTY MEDICAL CENTER   (United States)

^g Hospital Angeles de Torreon   (Mexico)

^h QUEEN ELIZABETH HOSPITAL   (Australia)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k Syreon Corporation   (Canada)

^l INDIANA UNIVERSITY   (United States)

more..

Author keywords

Immunosuppression; Kidney; Rejection.; Sirolimus; Transplantation

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; AGED; ANASTOMOSIS LEAKAGE; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER CANCER; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RESPIRATORY TRACT DISEASE; SEPSIS; STROKE; THROMBOCYTOPENIA; URINARY TRACT INFECTION; WOUND COMPLICATION; WOUND DEHISCENCE;

ALGORITHMS; ANEMIA; COHORT STUDIES; CREATININE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; OBSERVER VARIATION; PROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; URINARY TRACT INFECTIONS;

EID: 70350458840     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b9d0da     Document Type: Article

References (42)

1. AugustineJ, Bodziak K,Hricik D. Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369.
2. Neuhaus P, Klupp J, Langrehr J. mTOR inhibitors: An overview. Liver Transpl 2001; 7: 473.
3. Law B. Rapamycin: An anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005; 56: 47.
4. Kahan B; for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. Lancet 2000; 356: 194.
5. MacDonaldA; Rapamune Global Study Group.Aworldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclo-sporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
6. Ciancio G, Burke G, Gaynor J, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77: 244.
7. Gonwa T, Mendez R, Yang H, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 2003; 75: 1213.
8. Mendez R, Gonwa T, Yang H, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at1year.Transplantation2005; 80: 303.
9. Ciancio G, Burke G, Gaynor J, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252.
10. Kahan B, Kramer W. Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin Pharmacol Ther 2001; 70: 74.
11. Kahan B. Sirolimus: A comprehensive review. Expert Opin Pharmaco-ther 2001; 2: 1903.
12. Knight R, Kahan B. The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity? Kidney Int 2006; 70: 994.
13. Mulay A, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748.
14. Webster A, Lee V, Chapman J, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
15. Mulay A, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006; 82: 1153.
16. Flechner S, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
17. Groth C, Backman L, Morales J, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036.
18. Kreis H, Cisterne J, Land W, et al. Sirolimus in association with myco-phenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
19. Stegall M, Larson T, Prieto M, et al. Kidney transplantation without cal-cineurin inhibitors using sirolimus. Transplant Proc 2003; 35(suppl 3): 125S.
20. Machado P, Garcia C, Felipe C, et al. A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results. Transplant Proc 2001; 33: 1074.
21. Briggs A, Levy A. Pharmacoeconomics and pharmacoepidemiology: Curious bedfellows or a match made in heaven? Pharmacoeconomics 2006; 24: 1079.
22. Lo Re V III, Strom BL. The role of academia and the research community in assisting the food and drug administration to ensure U.S. drug safety. Pharmacoepidemiol Drug Saf 2007; 16: 818.
23. EtminanM, Samii A.PharmacoepidemiologyI:Areview of pharmaco-epidemiologic study designs. Pharmacotherapy 2004; 24: 964.
24. Hennessy S. Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 311.
25. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878.
26. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887.
27. MacDonald KM, Vancayzeele S, Deblander A, et al. Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: Application to mild and moderate dementia. Nurs Clin North Am 2006; 41: 105.
28. Kaufman D, Shapiro R, Lucey M, et al. Immunosuppression: Practice and trends. Am J Transplant 2004; 4(suppl 9): 38.
29. Larson T, Dean P, Stegall M, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
30. Undre N. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003; 18(suppl 1): i12.
31. Baldan N, Rigotti P, Furian L, et al. Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients. Pharmacol Res 2006; 54: 181.
32. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 2273.
33. Meier-Kriesche HU, Steffen BJ, Chu AH, et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004; 4: 2058.
34. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583.
35. Lee V, Chapman J. Sirolimus: Its role in nephrology. Nephrology (Car-lton) 2005; 10: 606.
36. Ciancio G, Burke GW, Gaynor JJ,etal. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cy-closporine/sirolimus in renal transplantation: Three-year analysis. Transplantation 2006; 81: 845.
37. Port F. Role of observational studies versus clinical trials in ESRD research. Kidney Int 2000; 57: S3.
38. Greene T. Are observational studies 'just as effective' as randomized clinical trials? Blood Purif 2000; 18: 317.
39. Jepsen P, Johnsen S, Gillman M, et al. Interpretation of observational studies. Heart 2004; 90: 956.
40. Kreis H, Oberbauer R, Campistol J, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809.
41. Oberbauer R, Segoloni G, Campistol J, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
42. Citterio F, Sparacino V, Altieri P, et al. Addition of sirolimus to cyclo-sporine in long-term kidney transplant recipients to withdraw steroid. Transplant Proc 2005; 37: 827